Altogether, our study showed the tumor inhibition effect of DHX9-HDAC5-BECN1 axis in ER+ and TNBC cell lines, implying the therapeutic potential of DHX9 or HDAC5 inhibitors in at least HR+ or TNBC subtypes. The gene discussed is DHX9; the disease is neoplasm.